Effects of pravastatin, phytosterols, and combination therapy on lipid profile in HIV-infected patients: an open-labelled, randomized cross-over study

BMC Research Notes

Table 2 Baseline characteristics of subjects

	Mean ± SD or median (min,max) or number (%)				p value
	Group 1 (n = 11)	Group 2 (n = 9)	Group 3 (n = 8)	Group 4 (n = 8)	p value
Age, year	47.94 ± 7.73	45.33 ± 8.66	41.12 ± 7.72	43.00 ± 7.41	0.23^b
BMI, kg/m²	22.48 ± 2.40	22.68 ± 3.64	23.63 ± 3.07	21.61 ± 2.45	0.59^b
Male, no.	8 (72.7)	7 (77.8)	4 (50)	4 (50)	0.48^c
Diabetes, no.	0	1 (11.1)	0	0	0.41^c
Hypertension, no	1 (9.1)	1 (11.1)	0	0	0.48^c
PIs, no.	2 (18.2)	1 (11.1)	0	1 (12.5)	0.50^c
NNRTI, no.	9 (81.8)	8 (88.9)	8 (100)	7 (87.5)	0.50^c
Suppressed HIV viral load, no^d	9 (81.8)	8 (88.9)	8 (100)	8 (100)	0.27^c
HIV duration, years	5.61 ± 5.21	11.11 ± 3.79	6.61 ± 4.51	8.78 ± 7.11	0.13^b
CD4, cell/cmm	514.27 ± 331.71	678.22 ± 438.85	612.62 ± 270.87	443.88 ± 152.96	0.45^b
Creatinine, mg/dL	0.90 ± 0.19	0.95 ± 0.28	0.94 ± 0.35	0.73 ± 0.13	0.29^b
SGPT, mg/dL	35.81 ± 24.46	35.66 ± 15.02	30.13 ± 12.77	27.50 ± 8.18	0.67^b
HDL-c, mg/dL	52.07 ± 13.23	53.04 ± 12.08	57.73 ± 20.93	58.13 ± 23.15	0.83^b
LDL-c, mg/dL	175.75 ± 36.90	186.99 ± 24.60	163.01 ± 9.65	173.04 ± 35.24	0.43^b
TC, mg/dL	222.0 (197,301)	245.0 (227,353)	242.5 (191,285)	242.0 (202,297)	0.48^a
TG, mg/dL	134.0 (64,390)	176.00 (53,620)	106.50 (58,499)	109.0 (52,367)	0.54^a
CPK, mg/dL	131.0 (46,876)	150.0 (87,234)	133.5 (60,289)	123.0 (79,532)	0.96^a

Group 1, pravastatin then combination; Group 2, combination then pravastatin; Group 3, phytosterols then combination; Group 4, combination then phytosterols.
^aKruskal–Wallis Test.
^bOne-way ANOVA.
^cLikelihood Ratio test.
^dSuppressed HIV viral load defined by HIV viral load <50 copies/ml.